「asi」の検索結果

Handles BED-format genomic intervals (BED3 through BED12, narrowPeak/broadPeak) and the coordinate-system substrate the whole interval category rests on, with bedtools (CLI) and pybedtools/pyranges/pandas (Python). Covers the 0-based half-open vs 1-based-closed convention boundary and the start-1/end-unchanged conversion, the silent failures (chrom-name mismatch, CRLF, lexicographic-vs-version sort under -sorted), genome/chrom.sizes generation, sorting contracts, BED12 block invariants, validation, makewindows, cross-assembly liftover (liftOver/CrossMap), and BED<->VCF/BAM/FASTA conversion. Use when reading, creating, validating, sorting, lifting between genome builds, or converting interval files, preparing inputs for bedtools/tabix/bigBed, or debugging an off-by-one or empty-overlap result.

日本語の概要は準備中です。原文の説明を表示しています。

Designs donor/repair templates for precise CRISPR knock-ins -- choosing the format (ssODN, long-ssDNA/Easi-CRISPR, dsDNA/plasmid, AAV6), sizing homology arms, placing the cut within ~10 bp of the edit, and adding a mandatory codon-checked blocking (PAM/seed) mutation so the edited allele is not re-cut. Frames the HDR-vs-NHEJ-vs-MMEJ pathway competition, the MMEJ (PITCh) and homology-independent (HITI/HMEJ) alternatives for post-mitotic cells, ssODN strand/asymmetry choice, phosphorothioate end-protection, and ranked HDR enhancers. Use when designing a donor for a point mutation, epitope/fluorophore tag, allele replacement, or knock-in, or when HDR efficiency is low. Guide design and base/prime editing are separate skills.

日本語の概要は準備中です。原文の説明を表示しています。

Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.

日本語の概要は準備中です。原文の説明を表示しています。

Assigns isolate identity at the right resolution for the question -- ANI / Mash species triage, 7-locus MLST historical comparability, cgMLST / wgMLST outbreak resolution (chewBBACA, BIGSdb, Ridom SeqSphere, EnteroBase HierCC), in-silico serotyping (SISTR, SeqSero2 for Salmonella; SerotypeFinder for E. coli; Kaptive K/O for Klebsiella; SeroBA for pneumococcus; spa + SCCmec for S. aureus), and lineage callers (TB-Profiler / Mykrobe Coll-Napier barcode for MTBC, Pangolin + Nextclade for SARS-CoV-2, PopPUNK GPSC for S. pneumoniae). Use when typing bacterial isolates for surveillance or outbreak investigation, choosing between cgMLST allele distance and core-SNP distance for cluster definition, harmonising calls across schemas / database versions (chewBBACA vs Ridom vs EnteroBase), assigning MTBC lineage with the Napier 2020 90-SNP barcode, calling Salmonella serovar via SISTR with monophasic Typhimurium awareness, running Pangolin UShER mode with explicit pangolin-data version pinning, or selecting a typing resolution to match the surveillance question.

日本語の概要は準備中です。原文の説明を表示しています。

Performs differential expression on bulk RNA-seq count data with DESeq2's negative-binomial GLM, Wald and LRT testing, apeglm/ashr/normal LFC shrinkage, independent filtering, Cook's outlier handling, VST/rlog transforms, and design formulas including paired, batch, and interaction terms. Use when running bulk DE, choosing DESeq2 over edgeR or limma-voom, building a paired or interaction design, applying LFC shrinkage for ranking or GSEA, choosing Wald vs LRT, troubleshooting padj=NA, picking VST vs rlog, importing salmon/kallisto via tximport, or analyzing prokaryotic RNA-seq.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes time-series and longitudinal RNA-seq for differential expression and trajectory structure. Covers DESeq2 LRT with reduced models, time as factor vs continuous vs natural splines, maSigPro (Nueda 2014 for RNA-seq), ImpulseDE2 with explicit impulse-model failure modes, DREAM for repeated measures via linear mixed models, pseudoreplication avoidance, conditional vs marginal modeling, and trajectory clustering with DPGP, Mfuzz (with Schwämmle 2010 fuzzifier estimation), and splines+k-means. Use when modeling time-course or longitudinal expression, choosing factor vs spline, handling repeated measures from the same subject, avoiding pseudoreplication, clustering temporal trajectories, or selecting between dedicated time-course tools and pairwise+LRT.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and analyzes in vivo CRISPR screens in animal tumor models, organoids, and immune-cell adoptive transfers. Covers bottleneck math (250x cells/sgRNA requires ~25M cells implanted; impossible for most syngeneic models, forcing focused libraries), focused library design (Manguso 2017 Nature 547:413 immune screen; Chen 2015 tumor screens), CRISPR-StAR intrinsic-control screening (Uijttewaal 2025 Nat Biotechnol 43:1848), clonal-dynamics-limited detection, tumor-explant DNA recovery, syngeneic vs xenograft vs PDX considerations, and the relationship to downstream MAGeCK / drugZ analysis. Use when designing in vivo CRISPR screens for tumor / immune / metastasis biology, choosing focused vs genome-wide for animal models, addressing bottleneck-induced clonal collapse, picking the syngeneic / xenograft / PDX model, integrating in vivo with in vitro results, or applying CRISPR-StAR for animal experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Resolve subclonal copy number, whole-genome doubling, and copy-number tumor evolution from bulk sequencing with Battenberg, TITAN, and MEDICC2. Covers clonal versus subclonal copy-number states, haplotype phasing for subclonal resolution, cancer cell fraction, whole-genome-doubling detection and timing relative to mutations, mirrored subclonal allelic imbalance, and copy-number phylogenies. Use when a tumor is heterogeneous and bulk data shows non-integer copy number, when calling subclonal CNAs, detecting or timing whole-genome doubling, reconstructing copy-number evolution, or deciding between Battenberg and TITAN.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Detect positive (diversifying / episodic / pervasive) selection using codon dN/dS frameworks. Implements PAML codeml site models (M0/M1a/M2a/M7/M8/M8a), branch models, branch-site model A (Zhang 2005), and HyPhy methods (BUSTED, BUSTED-S, BUSTED-MH, BUSTED-PH, MEME, FEL, FUBAR, aBSREL, SLAC, RELAX, GARD, FUBAR-MH). Includes McDonald-Kreitman framework (asymptotic alpha, impMKT, polyDFE, DFE-alpha, GRAPES) for within-species + divergence inference, RERconverge for trait-correlated rate shifts, CSUBST for convergent substitution, and PhyloAcc for accelerated noncoding evolution. Use when testing adaptive evolution at codons, branches, or full gene; running GARD recombination pre-screen; controlling alignment-error and gBGC false positives; reconciling PAML vs HyPhy results; or performing genome-scale selection scans.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses RNA-seq data quality specifically for alternative splicing analysis. QC layers include experimental design audit (library prep, read length, depth, replicates), STAR 2-pass cohort-style alignment, junction saturation curves and discovery plateau detection, novel-vs-known junction ratio diagnostics, junction-overhang distribution, splice-site strength scoring (MaxEntScan intrinsic + SpliceAI context-aware), strandedness verification, GENCODE basic vs comprehensive choice, and rRNA contamination screening. Splicing analysis is more demanding than DGE on read length, depth, library prep, alignment strategy, and annotation choice — failures silently bias PSI estimates and inflate novel-junction false positives. Use when evaluating data suitability for splicing analysis, troubleshooting low event detection, or designing sequencing experiments where AS is a primary endpoint.

日本語の概要は準備中です。原文の説明を表示しています。

View, convert, and understand SAM/BAM/CRAM alignment files using samtools and pysam. Use when inspecting alignments, converting between formats, or understanding alignment file structure.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a carrier asks about tire program design, when to retread vs replace, position management (steer vs drive vs trailer), inflation pressure standards, casing management, scrub rates, road-call prevention, or vendor program selection (Bridgestone, Michelin, Continental, Goodyear). Covers 49 CFR 393.75 and DOT roadside out-of-service criteria.

日本語の概要は準備中です。原文の説明を表示しています。

Use when an owner-operator (1099 or LLC/S-corp) asks how to lower their tax bill, what they can deduct, per diem treatment, depreciation choices (Section 179, bonus, MACRS), quarterly estimated payments, S-corp salary vs distributions, retirement plan options (SEP-IRA, Solo 401(k)), or recordkeeping requirements. Covers federal income tax + self-employment tax basics; not state-specific.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about hazardous materials (hazmat) transportation under 49 CFR 171-180 — placarding requirements, segregation tables, hazmat employee training (49 CFR 172 Subpart H), Hazmat Safety Permit (HMSP), shipping papers, packaging groups, emergency response phone, security plans, hazmat endorsement on CDL, and bulk vs non-bulk distinctions. Cite specific 49 CFR section.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about the FMCSA Drug & Alcohol Clearinghouse — full vs limited query, pre-employment vs annual query, query credit purchasing, who has access (employers, drivers, MROs, SAPs, state licensing agencies), reporting violations to the Clearinghouse, the "prohibited" status workflow, consent forms, or how to register/use the clearinghouse.fmcsa.dot.gov portal. Cite 49 CFR 382.701-727.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about carrier-driver relationships — Independent Contractor (IC / 1099) vs Employee (W-2), Owner-Operator lease agreements, the AB5 California law, the DOL 2024 IC test, lease-purchase programs from the carrier side, settlement statements, deductions, and how to structure a compliant IC arrangement. Cite 49 CFR 376 + 1099 IRS rules.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about DataQ — FMCSA's data review system at dataqs.fmcsa.dot.gov — for disputing inspection violations, crash records, or other entries that appear in a carrier's CSA / SMS score. Covers Request for Data Review (RDR) process, success rates, common dispute grounds, what evidence to attach, timeline expectations, and how successful disputes reduce BSI (BASIC Severity Indicator) scores. Cite 49 CFR 392.7 and the FMCSA DataQs User Guide.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to understand how FMCSA calculates the Crash Indicator BASIC. Covers what crashes count, severity weighting, time weighting, and the preventability program.

日本語の概要は準備中です。原文の説明を表示しています。

Improve Coval trace quality after basic ingestion works. Use when traces are sparse, missing useful STT/LLM/TTS/tool spans, missing attributes needed for Coval built-in metrics, or when a customer wants maximum debugging and observability value from agent traces.

日本語の概要は準備中です。原文の説明を表示しています。

Decision-ready scouting record for a user-connected provider access campaign. Use when an assigned Provider Access Launch task needs its easiest official route, minimum scopes, cost, account needs, approval path, implementation consumer, and easy-execute verdict established before submission. NOT for client Local Listings distribution.

日本語の概要は準備中です。原文の説明を表示しています。

RichDocument action toolkit for markdown and interactive content outside live chat. Use when adding an action or content source, wiring a remote action surface, putting actions on a MarkdownStream/BasicMarkdownContent preview, or touching features/rich-document/**, <RichDocument>, <RichDocumentActionSurface>, registerAction, ContentSourceAdapter, or enableContextMenu. NOT for the live chat message bar (use overlay-system).

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to inspect Sentry issues or events, summarize recent production errors, or pull basic Sentry health data via the Sentry API; perform read-only queries with the bundled script and require `SENTRY_AUTH_TOKEN`.

日本語の概要は準備中です。原文の説明を表示しています。